Austco Healthcare Trading Update and Guidance Upgrade

• Revenue up over 37% to $80-$82 million
• EBITDA up over 54% to $12.5-$13.5 million
• Amentco acquisition outperforms expectations

Austco Healthcare Limited (ASX: AHC) today provides guidance for the financial year ended 30 June 2025 (unaudited), highlighting strong year-on-year growth, disciplined execution of its strategic plan, and continued investment in long-term growth. The company's FY25 growth was driven by a combination of strong organic performance and contributions from strategic acquisitions, including the Amentco Enterprise Group Pty Ltd acquisition, which delivered results ahead of expectations in the second half of FY25. The $7.4 million upfront cash payment for the acquisition of G&S Technologies Limited was fully funded through operating cash flows, while the company also increased its cash position to $14.4 million. Austco's unfilled contracted revenue currently stands at $55.8 million, up from $50.2 million reported in February 2025. The company also expects a final earn-out payment of approximately $8.4 million for the Amentco acquisition, exceeding the previously accrued amount of $5.9 million.

Revenue of $80 - $82 million, EBITDA of $12.5 - $13.5 million, and cash at bank of $14.4 million for the financial year ended 30 June 2025.

With robust contracted revenue and momentum across key markets, Austco enters FY26 with confidence.